• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Resistance to gonadotropin-releasing hormone agonist in a patient with metastatic prostate cancer.

作者信息

Krongrad A, Brady J, Rodriguez R J

出版信息

South Med J. 1997 Apr;90(4):460-1. doi: 10.1097/00007611-199704000-00025.

DOI:10.1097/00007611-199704000-00025
PMID:9114847
Abstract
摘要

相似文献

1
Resistance to gonadotropin-releasing hormone agonist in a patient with metastatic prostate cancer.一名转移性前列腺癌患者对促性腺激素释放激素激动剂产生耐药性。
South Med J. 1997 Apr;90(4):460-1. doi: 10.1097/00007611-199704000-00025.
2
Failure of gonadotropin-releasing hormone agonists with and without sterile abscess formation at depot sites: insight into mechanisms?促性腺激素释放激素激动剂在注射部位有无无菌性脓肿形成时的失效情况：对机制的深入了解？
Urology. 2006 May;67(5):1084.e15-7. doi: 10.1016/j.urology.2005.11.015.
3
Bilateral orchidectomy in three metastatic prostate cancer patients with failed LHRH-agonist therapy.
S Afr Med J. 2006 Sep;96(9):810-1.
4
[Diferelin treatment of primary local and generalized cancer of the prostate].
Urologiia. 2001 Nov-Dec(6):17-9.
5
Bisphosphonate therapy for hormone refractory prostate cancer with bone metastasis.双膦酸盐疗法用于治疗伴有骨转移的激素难治性前列腺癌。
J Urol. 2003 Jan;169(1):281-2. doi: 10.1016/S0022-5347(05)64093-1.
6
Treatment of an orchiectomized patient with hormone-refractory prostate cancer with LH-RH agonists.用促性腺激素释放激素（LH-RH）激动剂治疗去势的激素难治性前列腺癌患者。
Eur Urol. 2001 Oct;40(4):474-6; discussion 477. doi: 10.1159/000049819.
7
Failure to maintain the suppressed level of serum testosterone during luteinizing hormone-releasing hormone agonist therapy in a patient with prostate cancer.在一名前列腺癌患者的促黄体生成素释放激素激动剂治疗期间，未能维持血清睾酮的抑制水平。
Int J Urol. 2002 Jun;9(6):359-61. doi: 10.1046/j.1442-2042.2002.00476.x.
8
Targeting FSH in androgen-independent prostate cancer: abarelix for prostate cancer progressing after orchiectomy.针对雄激素非依赖性前列腺癌的促卵泡激素（FSH）：阿巴瑞克用于睾丸切除术后进展的前列腺癌
Urology. 2004 Feb;63(2):342-7. doi: 10.1016/j.urology.2003.09.045.
9
Combination of docetaxel, estramustine phosphate, and zoledronic acid in androgen-independent metastatic prostate cancer: efficacy, safety, and clinical benefit assessment.多西他赛、磷酸雌莫司汀和唑来膦酸联合治疗雄激素非依赖性转移性前列腺癌：疗效、安全性及临床获益评估
Urology. 2005 Jan;65(1):126-30. doi: 10.1016/j.urology.2004.08.041.
10
High dose hook effect in serum total and free prostate specific antigen in a patient with metastatic prostate cancer.一名转移性前列腺癌患者血清总前列腺特异性抗原和游离前列腺特异性抗原中的高剂量钩状效应
J Urol. 2001 Jul;166(1):213.

引用本文的文献

1
Failure to achieve castrate level of serum testosterone during luteinizing hormone-releasing hormone agonist therapy in a patient with prostate cancer.在接受黄体生成素释放激素激动剂治疗的前列腺癌患者中，未能达到去势水平的血清睾酮。
Anticancer Drugs. 2020 Nov;31(10):1099-1102. doi: 10.1097/CAD.0000000000000986.
2
Surgical castration in hormone-refractory metastatic prostate cancer patients can be an alternative for medical castration.对于激素难治性转移性前列腺癌患者，手术去势可作为药物去势的一种替代方法。
Adv Urol. 2012;2012:979154. doi: 10.1155/2012/979154. Epub 2011 Jun 15.